CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
APAC
CANADA

About Us

Conference

Partner With Us

  • Europe
    • US
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Biotech
    Cancer Immunotherapy
    Cell and Gene Therapy Companies
    Clinical Trial Management
    Drug Discovery and Development
    Genomics
    Therapeutics
    Women's Health
  • Biomanufacturing
    Biomanufacturing
    Bioprocessing
    CDMO
    Clinical Laboratory Services
    CRO
    Supplements
  • Business Services
    Clinical Research Training
    Life Science Consulting
    Life Science Logistics
    Life Science Marketing
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Postbiotica has been recognized by Life Sciences Review Magazine as the exclusive recipient of “Top 10 Biotech Startup in Europe - 2021,” based on our proprietary methodology, reflecting its position in the industry. This profile has been developed by the Life Sciences Review research and editorial team based on insights from an interview with , .

Postbiotica
Strengthening the Human Microbiota

Postbiotica

Prof. Maria Rescigno, Founder and CSO, PostbioticaProf. Maria Rescigno, Founder and CSO
The human microbiota, which resides on or within human tissues and biofluids, plays a crucial role in our physical and mental health. Microbiota can modulate and preserve host immune response through the production of active molecules called postbiotics. But that’s not all! Not only does microbiota produce a multitude of biochemical compounds necessary to protect us against pathogens, but it also strengthens immunity, improves metabolism, and helps sustain our regular brain function, among other things.

A rising industrial and urban lifestyle is taking us away from the beneficial microbiota diversity. And this is causing a significant change in a person’s microbiota composition (dysbiosis), disrupting the delicate and symbiotic relationship between humans and microbes and leading to an increase in inflammatory and autoimmune diseases.

Enter Postbiotica

Postbiotica is an innovative biotechnological company that aims to address such events of dysbiosis. “We, at Postbiotica, research, develop and produce different postbiotics to modulate and reinstate the immune response otherwise mediated by microbiota,” says Prof. Maria Rescigno, founder and Chief Scientific Officer (CSO) of Postbiotica To facilitate this, Postbiotica has developed and industrialised an innovative fermentation technology, PBTech®.

We, at Postbiotica, research, develop and produce different postbiotics to modulate and reinstate the immune response otherwise mediated by microbiota.

This technology makes it possible to derive an array of postbiotics from selected microbial strains, not containing living or inanimate cells or any fragment of them.“Our proprietary technology even allows us to develop different postbiotic products from the same strain of bacteria,” adds Maria. “By changing different elements of the PBTech process, we can control the type of postbiotics we produce and tailor them to serve different purposes, like activating the immune system.”

“Our motto is ‘from nature the future of healthcare.’ We generate natural products derived from the fermentation of microbes that are normally present in our body,” underscores Maria. What’s more? Since the PBTech technology does not rely on food fermentation, the final postbiotics no longer strictly follow the oral administration route. Rather, these compounds can be even administered through mucosal or ocular surfaces as well in a totally safe manner. This unique feature further expands the application of postbiotics developed by Postbiotica.

Drawing on these extensive capabilities, right now, Postbiotica is playing a key role in the development of new preventive and therapeutic treatments. The company is currently offering its PBTech postbiotics to some of the leading companies. Simultaneously, Postbiotica is also planning on bringing postbiotic products directly to the end consumers. “We have several projects in our pipeline, including eyedrop formulation for conjunctivitis, ‘functional’ skincare, gastroenterology and supportive care in cancer patients,” highlights Maria. “Exploring through these fields of intervention, we believe we have a promising future ahead of us,” says Maria. That being said, Maria also mentions, Holding S1, Private Equity beat all others on time in 2021 with a significant round of investments, is among the most convinced of the great further development of Postbiotica

Top 10 Biotech Startup in Europe - 2021
Current Issue

Company : Postbiotica

Management
Prof. Maria Rescigno, Founder and CSO
Giuseppe Penna, Founder and Scientific Advisor

Thank you for Subscribing to Life Science Review Weekly Brief

Life Sciences Review Europe
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review Europe. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesrevieweurope.com/postbiotica